TMV-083 / Institut Pasteur, Merck (MSD), University of Pittsburgh 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
  • ||||||||||  TMV-083 / Institut Pasteur, Merck (MSD), University of Pittsburgh
    P1/2 data, Journal:  A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease. (Pubmed Central) -  Apr 2, 2024   
    Here, we evaluate a measles virus (MV)-vectored vaccine expressing a stabilized prefusion SARS-CoV-2 spike (S) protein (MV-ATU3-S2P?F2A; V591) with demonstrated immunogenicity in mouse models (see companion article [J...This study uses a safe and effective measles vaccine as a platform for vaccination against SARS-CoV-2...After challenge, these AGMs produced less virus in mucosal secretions, for a shorter period, and had a reduced disease burden in the lungs compared to control animals. At necropsy, lower levels of viral RNA were detected in tissue samples from vaccinated animals, and the lungs of these animals lacked the histologic hallmarks of SARS-CoV-2 disease observed exclusively in the control AGMs.
  • ||||||||||  TMV-083 / Institut Pasteur, Merck (MSD), University of Pittsburgh
    Journal:  Use of Stability Modeling to Support Accelerated Vaccine Development and Supply. (Pubmed Central) -  Oct 28, 2021   
    It is demonstrated that modeling methodologies need to be tailored to the nature of the vaccine, the available prior knowledge, and the monitored attributes. Considering that the well-established strategies reported in ICH or WHO guidelines are not always broadly applicable to vaccines, this article represents an important source of information for vaccine researchers and manufacturers, setting the grounds for further discussion within the vaccine industry and with regulators.
  • ||||||||||  TMV-083 / Institut Pasteur, Merck (MSD), University of Pittsburgh
    Trial completion:  COVID-19-101: Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (clinicaltrials.gov) -  Jul 8, 2021   
    P1,  N=90, Completed, 
    Considering that the well-established strategies reported in ICH or WHO guidelines are not always broadly applicable to vaccines, this article represents an important source of information for vaccine researchers and manufacturers, setting the grounds for further discussion within the vaccine industry and with regulators. Active, not recruiting --> Completed
  • ||||||||||  TMV-083 / Institut Pasteur, Merck (MSD), University of Pittsburgh
    Enrollment closed, Trial completion date, Trial primary completion date:  COVID-19-101: Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine (clinicaltrials.gov) -  Apr 8, 2021   
    P1,  N=90, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Oct 2021 --> Jul 2021 | Trial primary completion date: Nov 2020 --> Jun 2021
  • ||||||||||  Coronavirus Vaccine / Institut Pasteur, Merck (MSD), University of Pittsburgh
    [VIRTUAL] Detection of SARS-CoV-2 by the first (RUO) commercial rapid multiplex PCR respiratory panel () -  May 22, 2020 - Abstract #ECCMID2020ECCMID_5866;    
    Our results are in line with the limit of detection provided by the manufacturer at 300 copies/mL. The analyzer and cartridge design allow its use in any laboratory, even not PCR-trained, but also permit point-of-care testing by direct use of the nasopharyngeal swab without further manipulation.